ERBB2 and breast cancer: The lack of significant variability across different anatomical sites represents an important finding, especially in view of the possible introduction of anti-HER2 agents for HER2-low patients in the future, since it reassures on the reliability of relapse BC phenotype irrespectively from the choice of the anatomical site to be subjected to biopsy.